The University of Chicago Header Logo

Connection

Kamil M. Yenice to Melphalan

Back to Details
This is a "connection" page, showing publications Kamil M. Yenice has written about Melphalan.
Kamil M. Yenice
Connection Strength
0.055
Melphalan
  1. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.